A Hyderabad-based regulatory consultant has also been referred to in the First Information Report (FIR) as an alleged intermediary in the dealings. The CBI has alleged that three applications submitted by Artura Pharmaceuticals were pending before Roy. The CBI case concerns alleged bribery in exchange for regulatory favours relating to pharmaceutical applications associated with WHO certification standards. The report also detailed the three pending applications, the alleged payment amounts, the proposed transaction on August 6 and the role attributed to the Hyderabad-based consultant. The allegations recorded in the FIR indicate a suspected criminal conspiracy involving the proposed exchange of illegal gratification for official favours in processing pharmaceutical regulatory applications.